Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: Cause for concern in the old-old

Archives of Internal Medicine

Volumn 162, Issue 5, 2002, Pages 561-568

  Soumerai, Stephen B ^a   McLaughlin, Thomas J ^a   Ross Degnan, Dennis ^a   Christiansen, Cindy L ^b,c   Gurwitz, Jerry H ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c Affairs Health Services Research and Development   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; ELDERLY CARE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0036184287     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.5.561     Document Type: Article

References (42)

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
2. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days
3. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial
4. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2
5. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction
6. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction
7. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction
8. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction
9. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction
10. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
11. ACC/AHA guidelines for the management of patients with acute myocardial infarction, 1999 update: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
12. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction
13. Quality of care for Medicare patients with acute myocardial infarction: A four-state pilot study from the Cooperative Cardiovascular Project
14. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: A randomized controlled trial
15. Recent trends in hospital mortality of acute myocardial infarction - The Worcester Heart Attack Study: Have improvements been realized for all age groups?
16. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction: National Registry of Myocardial Infarction
17. The effect of comorbidity on use of thrombolysis or aspirin in patients with acute myocardial infarction eligible for treatment
18. Delayed hospital presentation in patients who have had acute myocardial infarction
19. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
20. Coronary thrombolysis for the elderly: Is clinical practice really lagging behind evidence of benefit?
21. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years
22. Delayed thrombolytic treatment of older patients with acute myocardial infarction
23. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: Evidence for undertreatment in women and the elderly
24. The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: Comorbidity and outcomes after hip replacement
25. Guidelines for the early management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction)
26. Sex-based differences in early mortality after myocardial infarction: National Registry of Myocardial Infarction 2 Participants
27. The association between hospital volume and survival after acute myocardial infarction in elderly patients
28. Estimating causal effects from large data sets using propensity scores
29. A goodness-of-fit test for the multiple logistic regression model
30. The use of goodness-of-fit statistics in the development of logistic regression models
31. The TTOPP study: Lessons from an aborted trial
32. Thrombolytic therapy in the elderly
33. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial (Global Use of Strategies to Open Occluded Coronary Arteries)
34. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
35. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: Participants in the National Registry of Myocardial Infarction 2
36. Thrombolysis medication errors: Benefits of bolus thrombolytic agents
37. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: Patterns of use and outcomes
38. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes
39. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction
40. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project
41. Early β-blocker therapy for acute myocardial infarction in elderly patients